Here are the DEF 14A proxy statements from Tarsus Pharmaceuticals, Inc. (TARS) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow TARS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TARS filings page.
Tarsus Pharmaceuticals, Inc. is asking stockholders to vote at its fully virtual 2026 Annual Meeting on June 25, 2026. Investors will elect four Class III directors to serve until 2029, cast an advisory vote on executive compensation, and ratify Ernst & Young LLP as independent auditor for 2026.
The proxy explains how to attend and vote online and confirms 43,023,959 common shares were outstanding on April 27, 2026. It also outlines board structure, committee memberships, director pay, and a pay-for-performance program for executives, including cash bonuses funded at 108% of target and expanded use of stock options, RSUs, and new performance-based RSUs.